Nalbuphine Extended Release (Trevi Therapeutics)

纳布啡缓释制剂 (Trevi Therapeutics)

Report date: 2026/03/26 20:00:17

Base Information

Drug NameNalbuphine Extended Release (Trevi Therapeutics)
Drug Alias NameNalbuphine ERHaduvioT-111PW-4142NAL ER
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionMu opioid receptor antagonistsKappa opioid receptor antagonists
TargetsMu opioid receptorKappa opioid receptor
Therapy Area/IndicationsPrurigo NodularisOpioid-Related DisordersPruritus +[7
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesPoland +[14
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesPenwest Pharmaceuticals Co
China Registration ClassN/A

Develop Information

Active CompaniesTrevi Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsPrurigo NodularisCoughIdiopathic Pulmonary Fibrosis
Inactive IndicationsOpioid-Related DisordersPruritusPrurigo +[4

Other Information

ATC CodeN/A
Related LinksN/A